Alpelisib (BYL719)

目录号:S2814

Alpelisib (BYL719) Chemical Structure

Molecular Weight(MW): 441.47

Alpelisib (BYL719) 是一种有效的选择性PI3Kα抑制剂,在无细胞试验中IC50为 5 nM,对PI3Kβ/γ/δ具有极弱的作用。Phase 2。

规格 价格 库存 购买数量  
RMB 4864.29 现货
RMB 3034.22 现货
RMB 4650.12 现货
RMB 7115.91 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的3个实验数据:

  • AN3CA (B), JHUEM2 (D), and MFE296 (H) cells were treated with the indicated doses of BGJ398 and BYL719 alone or in combination for 96 hours, and an SRB assay was subsequently performed.

    Mol Cancer Ther, 2017, 16(4):637-648. Alpelisib (BYL719) purchased from Selleck.

    BYL719 induces Apoptosis in MM cells. The effect of increasing concentrations of BYL719 (0-2.5 umol/l) for 48 h on the apoptosis of MM1s cells. The effect of BYL719 on the apoptosis signalling; cleaved PARP, caspase 3, caspase 9 by Western blotting. MM, multple myeloma.

    Br J Haematol 2014 165(1), 89-101. Alpelisib (BYL719) purchased from Selleck.

  • A549 cell was trypsinized and plated at 50% confluence in DMEM. 16 hours later, BYL719 was added at final concentrations of 0, 1, 5, 10 and 20uM. Another 24 hours later, cells were harvested in RIPA with protease and phosphatase inhibitor cocktail. Total protein concentration was measured by BCA method. Lysates equivalent to 20ug total protein were subject to Western Blot, using total- AKT, pS473-AKT, pT286-CyclinD1 and beta-actin (internal control) antibodies.

    Alpelisib (BYL719) purchased from Selleck.

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述 Alpelisib (BYL719) 是一种有效的选择性PI3Kα抑制剂,在无细胞试验中IC50为 5 nM,对PI3Kβ/γ/δ具有极弱的作用。Phase 2。
靶点
PI3Kα [1]
(Cell-free assay)
5 nM
体外研究

BYL719抑制含有PIK3CA突变体的乳腺癌细胞系的增殖,与PI3K/Akt通路各种下游信号组分的抑制相关。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Detroit562 NHTzTIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUWwMlEuOTByIN88US=> M2rEdFczKGh? NULuWVdmUUN3ME2xMlExKM7:TR?= M1\6[lI2PTVyNUS5
SNU-1076 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;vNE4yNTFyMDFOwG0> NFrCV3U4OiCq M4XoS2lEPTB;Nj64NkDPxE1? NYjDToVmOjV3NUC1OFk>
SNU-1066 NWj4cZNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV:wMlEuOTByIN88US=> MVi3NkBp M3fXXWlEPTB;MT6xN{DPxE1? MlW4NlU2PTB3NEm=
FaDu NIrQVXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vkUVAvOS1zMECg{txO NVTFSpFYPzJiaB?= M1TXR2lEPTB;MUmuOlYh|ryP MXmyOVU2ODV2OR?=
SNU1041 NH3zR25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX[xepA3OC5zLUGwNEDPxE1? MXy3NkBp M1PuWmlEPTB;MkCuOlUh|ryP MYSyOVU2ODV2OR?=
SCC25 NXjLPXBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVGwMlEuOTByIN88US=> MYq3NkBp MljvTWM2OD12OT6zNEDPxE1? MmjJNlU2PTB3NEm=
BON-1 M4HBUmZ2dmO2aX;uJGF{e2G7 M{PRWFEwOTBizszN MYm0JIg> MY\pcohq[mm2czDQTVNMKCiDS2SgV4VzOzB6KTDhcoQhdVSRUlOxM|Ih[WO2aY\peIlmew>? NGT6UmUzPTB{NkK5Ni=>
QGP-1 MX3GeY5kfGmxbjDBd5NigQ>? MoH5NU8yOCEQvF2= MoroOEBp NG\3XHpqdmirYnn0d{BRUTONIDjBT3QhW2W{M{C4LUBidmRibWTPVmMyNzJiYXP0bZZqfGmncx?= M1vQTlI2ODJ4Mkmy
MG-63 NX3IfYx4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfHN2RKSzVyPU[g{txO97zOIFnDPVA:OjRizszN NFnyUlMzPDl4MUe5NC=>
HOS M3G0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTF3IN88Ug+9lCCLQ{mwQVQzKM7:TR?= NXjhd3dzOjR7NkG3PVA>
MOS-J Mn3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDmTWM2OD1zMDFOwG3wxIxiSVO5NF0{PiEQvF2= NXnDOGtGOjR7NkG3PVA>
POS-1 MkHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjJNFlKSzVyPUig{txO97zOIFnDPVA:OzZizszN NIT4WXQzPDl4MUe5NC=>
92.1 M1:5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYm1NFAuOjByMDDuUS=> MV21JIQ> MYnpcohq[mm2czD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEGNVDCoV4VzPDd|KTD1dEB1dyBzIN88US=> M{XwOVI1PTZ|NUSw
Mel270 NFrCVlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYm1NFAuOjByMDDuUS=> NGflXIs2KGR? NXzOcW5DcW6qaXLpeJMhfGinIIDoc5NxcG:{eXzheIlwdiCxZjDBT3QhMFOnckS3N{khfXBidH:gNUDPxE1? MUKyOFU3OzV2MB?=
Omm1.3 NX7nNo9LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPTWJVZPTByLUKwNFAhdk1? MlvPOUBl M{jlWolvcGmkaYTzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiQVvUJEhU\XJ2N{OpJJVxKHSxIEGg{txO MkWwNlQ2PjN3NEC=
Omm1 NIfJc5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGflZYY2ODBvMkCwNEBvVQ>? M17wcFUh\A>? M3jXcYlvcGmkaYTzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiQVvUJEhU\XJ2N{OpJJVxKHSxIEGg{txO M1rkU|I1PTZ|NUSw
C918 Mn[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHHfWQ2ODBvMkCwNEBvVQ>? Mmn2OUBl MmPxbY5pcWKrdIOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCDS2SgLHNmejR5MzmgeZAhfG9iMTFOwG0> MWWyOFU3OzV2MB?=
Mel290 NH\WdVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\JU2c2ODBvMkCwNEBvVQ>? NV[zdZlwPSCm M3fxcolvcGmkaYTzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiQVvUJEhU\XJ2N{OpJJVxKHSxIEGg{txO M1ixNFI1PTZ|NUSw
OPM2 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DKWVAvPS1{LkWg{txO M3;YNVQ5KGh? NX;PNIh2cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Mn\6NlQ1ODVzMkG=
OPM1 MmHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITRZmcxNjVvMj61JO69VQ>? M4iyVlQ5KGh? MXTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M1Oxc|I1PDB3MUKx
U266 MkCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7Pc4wxNjVvMj61JO69VQ>? Mo\LOFghcA>? NF75d2pqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M{eyNlI1PDB3MUKx
MM1R NGH4Rm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWCwMlUuOi53IN88US=> NXrIdJVMPDhiaB?= M2jPRolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz Mn7HNlQ1ODVzMkG=
MM1S NX21doZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWf3ZVVsOC53LUKuOUDPxE1? NVm5elNmPDhiaB?= MW\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NWfm[2h5OjR2MEWxNlE>
H929 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jXXlAvPS1{LkWg{txO NIfZ[5I1QCCq NX7KVXZmcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Mnr5NlQ1ODVzMkG=
RPMI NGPUfnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTNZXpnOC53LUKuOUDPxE1? MVe0PEBp MXXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M{DrPFI1PDB3MUKx
SKBR3 MoPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\1eVM{KM7:TR?= M2LmXVUh\A>? M1LiZYlvcGmkaYTzJFM297zHIHPlcIwh\3Kxd4To MlTBNlM6OTh5OUe=
MDA453 MmH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nZflM{KM7:TR?= NH\HdXc2KGR? MXvpcohq[mm2czCzPQ+9jSClZXzsJIdzd3e2aB?= Ml:wNlM6OTh5OUe=
EFM192A MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXOWlFwOzNizszN Mle1OUBl MX7pcohq[mm2czCyO-+9jSClZXzsJIdzd3e2aB?= M2HuelI{QTF6N{m3
AU565 MoX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13qUVM{KM7:TR?= MY[1JIQ> NEOweHZqdmirYnn0d{AzPu,:hTDj[YxtKGe{b4f0bC=> NGPSPZUzOzlzOEe5Oy=>
MDA361 NEXxOo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDp[4o{OyEQvF2= M3zmZlUh\A>? MYHpcohq[mm2czC0OQ+9jSClZXzsJIdzd3e2aB?= MVSyN|kyQDd7Nx?=
BT474 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7YT3k{OyEQvF2= MXi1JIQ> NFnV[3NqdmirYnn0d{AyPu,:hTDj[YxtKGe{b4f0bC=> NU\k[GdZOjN7MUi3PVc>
HCC202 MmDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\0Sm0{OyEQvF2= NULxXHhuPSCm MXvpcohq[mm2czCyNQ+9jSClZXzsJIdzd3e2aB?= M4CyUlI{QTF6N{m3
KPL4 M4TFcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPqTY1uOzNizszN MnPQOUBl NWPCenpxcW6qaXLpeJMhPTkxvJWgZ4VtdCCpcn;3eIg> M1n0OFI{QTF6N{m3
NCL-N87 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGm0bII{OyEQvF2= NVrFR4o1PSCm MnHJbY5pcWKrdIOgN|HwxIViY3XscEBoem:5dHi= MV[yN|kyQDd7Nx?=
UACC812 M4G2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWCzN{DPxE1? MlPIOUBl M37hfYlvcGmkaYTzJFI497zHIHPlcIwh\3Kxd4To MX[yN|kyQDd7Nx?=
HCC2218 NHLZOIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3XboVqOzNizszN M3iwUVUh\A>? M1njNolvcGmkaYTzJFE297zHIHPlcIwh\3Kxd4To NUPnOldFOjN7MUi3PVc>
HCC1569 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHXeJM{OyEQvF2= NEewVIc2KGR? NV36[HJwcW6qaXLpeJMhPe,:hTDj[YxtKGe{b4f0bC=> MlKzNlM6OTh5OUe=
OE19 NFzOT|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTVWG43OzNizszN MY[1JIQ> MmTTbY5pcWKrdIOgNlPwxIViY3XscEBoem:5dHi= MVqyN|kyQDd7Nx?=
OE33 MkXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LxWFM{KM7:TR?= MnLyOUBl NWPIUphlcW6qaXLpeJMhOjQxvJWgZ4VtdCCpcn;3eIg> NYnhUIF4OjN7MUi3PVc>
JIMT1 NH\LWVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjGOGY{OyEQvF2= Mm\wOUBl M37KVIlvcGmkaYTzJFnwxIViY3XscEBoem:5dHi= M2rncVI{QTF6N{m3
HCC1954 MonvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYKzN{DPxE1? M{npW|Uh\A>? MnnGbY5pcWKrdIOgNlnwxIViY3XscEBoem:5dHi= NFnUSIUzOzlzOEe5Oy=>
NUGC4 MmPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jQRlM{KM7:TR?= NY[5OJN5PSCm NGfGXolqdmirYnn0d{AyPO,:hTDj[YxtKGe{b4f0bC=> NX25O|dLOjN7MUi3PVc>
ZR-75-30 NYj1XFRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXWzN{DPxE1? MWe1JIQ> MYfpcohq[mm2czCtNVXwxIViY3XscEBoem:5dHi= NGn2U4UzOzlzOEe5Oy=>

... Click to View More Cell Line Experimental Data

体内研究 BYL719(>270 mg/d)在PIK3CA突变体异种移植啮齿动物模型中表现出统计学显著的剂量依赖性抗肿瘤效能。BYL719具有低清除率,半衰期为8.5小时,并且它的作用在30mg/d 和450mg/d之间剂量成比例的增加,在人的Cmax 和AUC中显示出低的个体差异。BYL719(270mg/d)首次表现出临床疗效的迹象,包括在ER+乳腺癌患者中证实的部分响应,以及17个患者中8个实现了显著的PET响应(PMR)和/或肿瘤治愈。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

溶解度 (25°C)

体外 DMSO 88 mg/mL (199.33 mM)
Ethanol 2 mg/mL (4.53 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
30% PEG400+0.5% Tween80+5% propylene glycol
30 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 441.47
化学式

C19H22F3N5O2S

CAS号 1217486-61-7
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02058381 Active not recruiting Pre-menopausal Breast Cancer|PI3K Pathway Inhibition Novartis Pharmaceuticals|Novartis May 6 2014 Phase 1
NCT02051751 Completed Neoplasms Breast Neoplasms Head and Neck Neoplasms Novartis Pharmaceuticals|Novartis March 5 2014 Phase 1
NCT01219699 Active not recruiting Advanced Solid Tumors With an Alteration of the PIK3CA Gene|Estrogen Receptor Positive Breast Cancer Novartis Pharmaceuticals|Novartis October 5 2010 Phase 1
NCT03601507 Not yet recruiting CDKN2A-p16 Positive|Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma|Stage I Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7|Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7|Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 University of Arizona|National Cancer Institute (NCI) September 30 2018 Phase 2
NCT02282371 Active not recruiting Head and Neck Squamous Cell Cancer Memorial Sloan Kettering Cancer Center|Novartis Pharmaceuticals October 30 2014 Phase 1
NCT02155088 Active not recruiting Pancreatic Cancer H. Lee Moffitt Cancer Center and Research Institute|Novartis October 30 2014 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

相关PI3K产品

Tags: 购买Alpelisib (BYL719) | Alpelisib (BYL719)供应商 | 采购Alpelisib (BYL719) | Alpelisib (BYL719)价格 | Alpelisib (BYL719)生产 | 订购Alpelisib (BYL719) | Alpelisib (BYL719)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID